Analysts' Actions -- AbbVie, AstraZeneca, 3D Systems, Whirlpool and More

RATINGS CHANGES

AbbVie (ABBV) was initiated with a hold rating at Deutsche Bank. $63 price target. The company remains highly levered to Humira, which has an uncertain amount of exclusivity, Deutsche said. 

Axalta Coating Systems (AXTA) was upgraded to hold at TheStreet Ratings. You can view the full analysis from the report here: AXTA.

AstraZeneca (AZN) was downgraded to hold from buy at Jefferies. The company lacks near-term catalysts, Jefferies said. 

Cohen & Steers (CNS) was upgraded to buy from underperform at Bank of America/Merrill Lynch. $37 price target. The company is delivering organic growth in a tough environment, analysts said. 

3D Systems (DDD) was downgraded to underweight from neutral at JPMorgan. $10 price target. The stock is up 68% year-to-date, but the company has limited sales visibility, JPMorgan said. 

ITC (ITC) was downgraded to hold from buy at Deutsche Bank. The valuation isn't as attractive, based on a $43 price target, Deutsche said. 

Mohawk (MHK) was downgraded to neutral from overweight at JPMorgan. The valuation isn't as attractive, based on a $215 price target, JPMorgan said. 

Swift Transportation (SWFT) was upgraded to buy at TheStreet Ratings. You can view the full analysis from the report here: SWFT.

Tiffany (TIF) was downgraded to neutral from buy at Citigroup. $78 price target. The valuation isn't as attractive, as it is unclear when the business will rebound, Citigroup said. 

T. Rowe Price (TROW) was downgraded to neutral at Bank of America/Merrill Lynch, because the valuation isn't as attractive.

If you liked this article you might like

Arconic, Idexx Laboratories, AbbVie: 'Mad Money' Lightning Round

Don't Get Shaken Out of Good Stocks: Cramer's 'Mad Money' Recap (Wed 9/13/17)

AbbVie Is Likely to Correct: Book Some Profits

5 of the Most Popular Stocks Owned by Wall Street's Elite, Revealed

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst